The neurodegenerative disease market growth continues to demonstrate resilience as genetic insights transform our understanding of disease etiology and open new therapeutic avenues. Discovery of pathogenic mutations in genes such as APP, PSEN1, PSEN2, SNCA, LRRK2, C9orf72, and SOD1 has enabled the development of genetically defined patient subgroups and targeted intervention strategies. Rising...